Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. (symbol: GH) is a pioneering biotechnology company headquartered in Redwood City, California. The company specializes in liquid-based cancer tests, providing innovative diagnostic tools for both clinical and research purposes. Guardant Health is renowned for its comprehensive liquid biopsy solutions, which offer non-invasive methods to access and sequence tumor DNA.
The company's flagship products include:
- Guardant360 LDT: A liquid biopsy test that assists in treatment selection for advanced-stage cancer patients.
- Guardant360 CDx: An FDA-approved companion diagnostic for several targeted therapies, ensuring precise treatment plans.
- Guardant OMNI: A broad gene panel designed for immuno-oncology research, aiding in the understanding of cancer's genetic underpinnings.
- Reveal: Launched in 2021, this tumor-agnostic molecular residual disease (MRD) test helps monitor cancer recurrence or residual disease at the molecular level.
- Shield: Introduced in 2022, this lab-developed test offers a non-invasive screening option for colorectal cancer (CRC).
Guardant Health's cutting-edge technologies have been widely adopted by thousands of oncologists globally, benefiting tens of thousands of advanced cancer patients. The company has made significant strides in early cancer detection, with ongoing projects that promise to deliver profound impacts on patient care.
Financially, Guardant Health has raised over $500 million from prestigious investors such as Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank. This substantial backing underscores the confidence in Guardant's potential to revolutionize cancer diagnostics and treatment.
In addition to its product offerings, Guardant Health provides research development services, including regulatory approval consultancy and clinical trial referrals. These services are designed to support the seamless integration of their diagnostic tools into clinical practice and research settings.
Stay updated with the latest news and developments about Guardant Health, Inc. as the company continues to push the boundaries of cancer diagnostics and treatment.
Rhea-AI Summary
Cancer Research UK (CRUK) and Guardant Health, Inc. (Nasdaq: GH) have announced a collaboration to explore opportunities to accelerate the discovery and development of cancer drugs and diagnostics. The partnership will focus on sharing technologies, data, and insights to advance precision oncology, with a particular emphasis on CRUK's clinical trials, including the DETERMINE trial - the first UK national precision medicine trial in rare cancers. Guardant Health aims to further validate its technologies, including the InfinityTM platform, while providing support for those with rare cancers and others who could benefit from precision oncology. The collaboration also aims to apply data-driven insights and technologies to CRUK's detection and treatment studies, potentially accelerating the work of the Centre for Drug Development and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will present data at the San Antonio Breast Cancer Symposium, highlighting the role of blood tests in detecting minimal residual disease and predicting therapy response in breast cancer patients. The presentations will showcase the use of liquid biopsy tests to identify actionable biomarkers and predict recurrence in early-stage breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) announces the grant of 50,741 restricted stock units (RSUs) to 43 new non-executive employees under the 2023 Employment Inducement Incentive Award Plan. The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest on an annual basis, subject to each employee’s continued employment with Guardant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) to Appeal Verdict on Intellectual Property Claims
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
-
News
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) has launched its blood-based colorectal cancer screening test, ShieldTM, in collaboration with Samsung Medical Center in South Korea. The Shield test, which can detect cancer in its early stages by analyzing circulating tumor DNA (ctDNA), achieved 83% sensitivity and 90% specificity in a pivotal study. Early detection is crucial as colorectal cancer is one of the leading causes of cancer-related deaths in South Korea. The Shield test has shown approximately 90% adherence in a real-world clinical setting, addressing the low compliance rates associated with traditional screening methods.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
-
Rhea-AI Summary
Guardant Health, Inc. reported a 22% increase in Q3 revenue compared to the previous year, driven by a 35% growth in clinical volume. The company raised its 2023 revenue guidance to $553 to $556 million. Other highlights include the presentation of MRD data for the PEGASUS trial and the launch of Guardant360 in Japan and China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
Rhea-AI Summary
Guardant Health, Inc. (Nasdaq: GH) will be participating in two upcoming investor conferences: Jefferies 14th Annual Global Healthcare Conference in London, UK on November 16 at 9:00 a.m. GMT and Piper Sandler 35th Annual Healthcare Conference in New York, NY on November 28 at 9:30 a.m. ET. Interested parties can access live and archived webcasts of the sessions on the company website at www.guardanthealth.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
-
Rhea-AI Summary
Guardant Health and Flatiron Health announce an initiative to integrate Guardant's genomic profiling tests within Flatiron's OncoEMR tool. This integration streamlines access to critical data for over 2,000 clinicians within the Flatiron network, simplifying workflows and saving time in the ordering process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Initial results from the PEGASUS trial suggest that Guardant Health's circulating tumor DNA blood test can be used to guide post-surgical chemotherapy regimens for patients with stage III or high-risk stage II colon cancer. The study found that patients with positive liquid biopsy results had a higher risk of cancer recurrence, while those with negative results had a lower risk. The test can help reduce unnecessary toxicity from chemotherapy and improve treatment outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
Rhea-AI Summary
Guardant Health, Inc. will report Q3 2023 financial results on November 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
FAQ
What is the current stock price of Guardant Health (GH)?
The current stock price of Guardant Health (GH) is $32.65 as of November 22, 2024.
What is the market cap of Guardant Health (GH)?
The market cap of Guardant Health (GH) is approximately 4.0B.
What does Guardant Health, Inc. specialize in?
Guardant Health specializes in liquid-based cancer tests, providing non-invasive diagnostic tools for clinical and research use.
What are the main products offered by Guardant Health?
Guardant Health offers Guardant360 LDT, Guardant360 CDx, Guardant OMNI, Reveal, and Shield, which are various liquid biopsy tests for cancer detection and treatment selection.
What is Guardant360 CDx?
Guardant360 CDx is an FDA-approved companion diagnostic test used to guide targeted cancer therapies.
How does Guardant Health support cancer research?
Guardant Health aids cancer research through products like Guardant OMNI and services such as regulatory approval consultancy and clinical trial referrals.
What is the significance of the Reveal test?
Reveal is a tumor-agnostic molecular residual disease (MRD) test that helps monitor cancer recurrence or residual disease at the molecular level.
What is the purpose of the Shield test?
The Shield test is a non-invasive liquid biopsy for colorectal cancer (CRC) screening.
Who are some of the major investors in Guardant Health?
Guardant Health has received investments from Sequoia Capital, Khosla Ventures, Orbimed, and SoftBank.
Where is Guardant Health, Inc. headquartered?
Guardant Health, Inc. is headquartered in Redwood City, California.
What is the Guardant360 LDT test used for?
Guardant360 LDT is used for treatment selection in patients with advanced-stage cancer.
How does Guardant Health contribute to early cancer detection?
Guardant Health contributes to early cancer detection through its pioneering products and ongoing research in liquid biopsy technologies.
Guardant Health, Inc.
Nasdaq:GH
GH Rankings
GH Stock Data
4.02B
117.89M
4.56%
104.62%
8.33%
Diagnostics & Research
Services-medical Laboratories
United States of America
PALO ALTO